Janssen Search
Search results
DARZALEX® (daratumumab)-based regimens significantly improve clinical outcomes in both transplant-eligible and-ineligible patients who are newly diagnosed with multiple myeloma
Jun 03, 2024 88 percent of transplant-eligible patients achieved a complete response or better, and 47 percent of patients sustained MRD-negativity for longer than one year with DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj)-based induction, ...
Perinatal Depression
Article Block Text: Recognizing at-risk women to enable interception prior to disease impact. Article Type: Disease Interception Accelerator Perinatal Depression The World Health Organization has declared that maternal mental health disorders constitute ...
Gestational Diabetes Mellitus
Article Block Text: Using predictive biomarkers and monitoring to intervene pre-conception through pregnancy. Article Type: Disease Interception Accelerator Gestational Diabetes Mellitus Identification of women at risk through epidemiological modeling ...
Five Things We Know About Pulmonary Arterial Hypertension
Article Block Text: Article Type: Other Awareness & Advocacy Pulmonary Hypertension Five Things We Know About Pulmonary Arterial Hypertension Pulmonary arterial hypertension (PAH) is a deadly disease, but it can be managed—if you get a timely ...
Five Things We Know About Pulmonary Arterial Hypertension
Five Things We Know About Pulmonary Arterial Hypertension Pulmonary arterial hypertension (PAH) is a deadly disease, but it can be managed—if you get a timely diagnosis. Here is what the latest science and research has revealed about PAH, including who ...
RYBREVANT® (amivantamab-vmjw) plus chemotherapy show 49 percent overall response rate in metastatic colorectal cancer
Sep 14, 2024 Spain Median duration of response reaches 7.4 months with combination treatment in patients with aggressive form of disease New results show potential of RYBREVANT ® beyond lung cancer BARCELONA, September 14, 2024 – Johnson & Johnson ...
Post-Marketing Requirements
Article Type: Transparency Post-Marketing Requirements and Commitments For more than 75 years, Janssen has been helping improve health around the world. From early discovery to distribution, patient access and education, we continuously search for ways ...
Janssen Prevention Center
"To make a difference in these and other major areas of unmet medical need, our goal is to identify and research innovative solutions to extend people's healthy life span and compress morbidity.” Jaap Goudsmit, M.D., Ph.D. Global Head, Janssen ...
Solving Industry Challenges
Solving Industry Challenges Article Type: Human Microbiome Institute Today the microbiome is an exciting but evolving field and there are many scientific, regulatory, and commercial questions that must be answered in order to successfully translate ...
What is PAH
Pulmonary Arterial Hypertension (PAH) PAH affects people of all ages, impairing daily life and limiting survival. Our immediate goal is to prolong survival and we also aim to improve the quality of life for those living with this disease. PAH can occur ...